Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Policy
Court Backs GSK On Patent Rule Challenge
April 7, 2008
| A version of this story appeared in
Volume 86, Issue 14
The U.S. District Court of the Eastern District of Virginia has granted summary judgment to GlaxoSmithKline in support of the drug company's challenge to final rules issued by the U.S. Patent & Trademark Office that would limit the number of patent continuations and claim applications that can be presented to PTO. GSK argued that the rules, issued last August, would impede drug discovery and development (C&EN, Dec. 17, 2007, page 19). The court ruled that PTO lacked the authority to make substantive rule changes. In a statement, PTO expressed disappointment at the court's rejection.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X